ABBV AUG 2025ABBV is approaching a strong resistance zone after heavy selling volume near 210–215. The stock recently broke higher, but price is testing supply after a fast rally.
Institutional absorption was seen at 190 and 195, with 205 now acting as immediate support.
Upside target: 212–215 if buyers absorb
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.79 EUR
4.09 B EUR
54.42 B EUR
1.76 B
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
ISIN
US00287Y1091
FIGI
BBG00FZMGBN2
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
End of the Upward Impulse?
AbbVie is a large-cap healthcare company with ongoing sector-specific concerns.
Technically, impulsive upward waves seem to be completed.
Near-term indicators remain positive, but this optimism may only represent a point B.
Fair value for ABBV is around $190 and the current price reflects this.
Abbvie, maybe this time...
NYSE:ABBV has been very hard to trade...but with earnings behind us and good beat and guidance, I think this will run..
creating an ascending triangle here with higher highs into equal lows and a close above 197 next week could send this way past 200 IMO
healthcare sector is beaten down as it
Abbvie please go man lolNYSE:ABBV has tested my patience
has been in a downtrend for a while now and has finally broken out, is now above all MAs on the daily and above 50 SMA on the weekly
193 is a high volume node to cross and after that there is not much volume
targetting 200
ER coming up and expecting a very go
ABBV - Are you Ready?Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst.
📈ABBV has been in a correction phase and it is currently approaching the lower bound of the red and blue channels.
Moreover, the green zone is a strong round number $150 and structure!
🏹 Thus, the highlighte
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044Yield to maturity
—
Maturity date
Jun 15, 2044
ABBV4911718
AbbVie Inc. 4.25% 21-NOV-2049Yield to maturity
—
Maturity date
Nov 21, 2049
ABBV5758814
AbbVie Inc. 4.8% 15-MAR-2029Yield to maturity
—
Maturity date
Mar 15, 2029
ABBV6009165
AbbVie Inc. 5.2% 15-MAR-2035Yield to maturity
—
Maturity date
Mar 15, 2035
ABBV5759204
AbbVie Inc. 5.35% 15-MAR-2044Yield to maturity
—
Maturity date
Mar 15, 2044
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048Yield to maturity
—
Maturity date
Nov 14, 2048
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042Yield to maturity
—
Maturity date
Oct 1, 2042
ABBV5084339
AbbVie Inc. 2.95% 21-NOV-2026Yield to maturity
—
Maturity date
Nov 21, 2026
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064Yield to maturity
—
Maturity date
Mar 15, 2064
ABBV4693581
AbbVie Inc. 4.25% 14-NOV-2028Yield to maturity
—
Maturity date
Nov 14, 2028
ABBV5068390
AbbVie Inc. 4.75% 15-MAR-2045Yield to maturity
—
Maturity date
Mar 15, 2045
See all 4AB bonds
Curated watchlists where 4AB is featured.
Frequently Asked Questions
The current price of 4AB is 179.40 EUR — it has increased by 0.33% in the past 24 hours. Watch AbbVie, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AbbVie, Inc. stocks are traded under the ticker 4AB.
4AB stock has risen by 0.56% compared to the previous week, the month change is a 9.10% rise, over the last year AbbVie, Inc. has showed a 0.80% increase.
We've gathered analysts' opinions on AbbVie, Inc. future price: according to them, 4AB price has a max estimate of 218.47 EUR and a min estimate of 145.65 EUR. Watch 4AB chart and read a more detailed AbbVie, Inc. stock forecast: see what analysts think of AbbVie, Inc. and suggest that you do with its stocks.
4AB stock is 1.45% volatile and has beta coefficient of 0.36. Track AbbVie, Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie, Inc. there?
Today AbbVie, Inc. has the market capitalization of 317.45 B, it has increased by 0.82% over the last week.
Yes, you can track AbbVie, Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie, Inc. is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
4AB earnings for the last quarter are 2.52 EUR per share, whereas the estimation was 2.44 EUR resulting in a 3.12% surprise. The estimated earnings for the next quarter are 2.78 EUR per share. See more details about AbbVie, Inc. earnings.
AbbVie, Inc. revenue for the last quarter amounts to 13.09 B EUR, despite the estimated figure of 12.76 B EUR. In the next quarter, revenue is expected to reach 13.28 B EUR.
4AB net income for the last quarter is 787.78 M EUR, while the quarter before that showed 1.18 B EUR of net income which accounts for −33.21% change. Track more AbbVie, Inc. financial stats to get the full picture.
Yes, 4AB dividends are paid quarterly. The last dividend per share was 1.41 EUR. As of today, Dividend Yield (TTM)% is 3.08%. Tracking AbbVie, Inc. dividends might help you take more informed decisions.
AbbVie, Inc. dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 2, 2025, the company has 55 K employees. See our rating of the largest employees — is AbbVie, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie, Inc. EBITDA is 22.71 B EUR, and current EBITDA margin is 44.40%. See more stats in AbbVie, Inc. financial statements.
Like other stocks, 4AB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie, Inc. stock shows the strong buy signal. See more of AbbVie, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.